🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

307 results for “Disc Medicine” Clear

  1. Sitravatinib, Tislelizumab, Sitravatinib

    Disc Medicine

    Uveal melanoma

    phase 2 small molecule active

    1 trial

  2. Skyrizi 600 mg concentrate for solution for infusion

    Disc Medicine

    Inflammatory Bowel Disease (IBD)

    phase 2 small molecule active

    1 trial

  3. Skyrizi 600 mg concentrate for solution for infusion, Humira 40 mg solution for injection in pre-filled syringe

    Disc Medicine

    Inflammatory Bowel Disease (IBD)

    phase 2 small molecule active

    1 trial

  4. Sodium Chloride 0.9% w/v Intravenous Infusion BP Solution for Infusion., Cinryze 500 IU powder and solvent for solution for injection

    Disc Medicine

    aneurysmal subarachnoid hemorrhage

    phase 2 small molecule active

    1 trial

  5. Softisan 378, Cannabidiol

    Disc Medicine

    psychological disorders: PTSD; Anxiety disorders

    phase 2 small molecule active

    1 trial

  6. Subtyping Primary Aldosteronism with Para-chloro-2-[18F]fluoroethyl-etomidate ([18F]CETO)

    Disc Medicine

    Primary aldosteronism

    phase 2 other active

    1 trial

  7. TOPIRAMATE

    Disc Medicine

    human immunodeficiency virus 1 (HIV-1)

    phase 2 small molecule active

    1 trial

  8. Tecentriq 1 200 mg concentrate for solution for infusion

    Disc Medicine

    (Diffuse) Large B-cell Lymphoma

    phase 2 small molecule active

    1 trial

  9. Tecentriq 1 200 mg concentrate for solution for infusion, Tiragolumab

    Disc Medicine

    Squamous cell carcinoma of the anal canal

    phase 2 small molecule active

    1 trial

  10. Temozolomide Accord 180 mg hard capsules., Temozolomide Accord 250 mg hard capsules., Temozolomide Accord 5 mg hard capsules., Temozolomide SUN 5 mg hard capsules, Temozolomide Accord 20 mg hard capsules., Temozolomide SUN 180 mg hard capsules, Temozolomide SUN 250 mg hard capsules, Temozolomide Accord 100 mg hard capsules., Temozolomide SUN 140 mg hard capsules, Temozolomide Accord 140 mg hard capsules., Temozolomide SUN 100 mg hard capsules, Temozolomide SUN 20 mg hard capsules

    Disc Medicine

    Diffuse Midline Glioma, H3K27-altered

    phase 2 small molecule active

    1 trial

  11. Tiragolumab, Tecentriq 1 200 mg concentrate for solution for infusion

    Disc Medicine

    HNSCC, metastatic deficient mismatch repair (dMMR)/MSI-high (MSI-H) tumors, irresectable or metastatic melanoma, locally advanced or metastatic solid tumor

    phase 2 small molecule active

    1 trial

  12. YERVOY 5 mg/ml concentrate for solution for infusion, OPDIVO 10 mg/mL concentrate for solution for infusion.

    Disc Medicine

    castration-resistant prostate cancer

    phase 2 small molecule active

    1 trial

  13. Zr89

    Disc Medicine

    giant cell arteritis, rheumatoid arthritis

    phase 2 small molecule active

    1 trial

  14. [18F]-olaparib PET; Molecular imaging of DNA damage response by [18F]-olaparib PET

    Disc Medicine

    Head and neck squamous cell carcinoma (HNSCC)

    phase 2 other active

    1 trial

  15. [18F]Fluor-PEG-Folate

    Disc Medicine

    giant cell arteritis

    phase 2 small molecule active

    1 trial

  16. [18F]Tetrafluoroborate

    Disc Medicine

    Differentiated Thyroid Cancer

    phase 2 small molecule active

    1 trial

  17. [68Ga]FAPI-46

    Disc Medicine

    giant cell arteritis - polymyalgia rheumatica spectrum disease

    phase 2 small molecule active

    1 trial

  18. [68Ga]Ga-PentixaFor

    Disc Medicine

    Cardiac Sarcoidosis

    phase 2 small molecule active

    1 trial

  19. cRGD-ZW800-1

    Disc Medicine

    Oral cancer

    phase 2 small molecule active

    1 trial

  20. cRGD-ZW800-1

    Disc Medicine

    Squamous cell carcinoma of the larynx and hypopharynx

    phase 2 small molecule active

    1 trial

  21. 68GA-FAPI-46

    Disc Medicine

    Peritoneal metastases

    phase 1 small molecule active

    1 trial

  22. A phase I study investigating the local tolerability and pharmacokinetics of isoniazid (INH) inhalation by wet nebulization in patients with tuberculosis

    Disc Medicine

    Tuberculosis

    phase 1 other active

    1 trial

  23. Adoptive TIL therapy in combination with chemoimmunotherapy in advanced NSCLC patients

    Disc Medicine

    Respiratory tract diseases

    phase 1 other active

    1 trial

  24. AmBisome liposomale amfotericine B 50 mg, poeder voor oplossing voor infusie, TECHNETIUM (99MTC) PERTECHNETATE

    Disc Medicine

    Chronic pulmonary aspergillosis

    phase 1 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources